Research Article
Promoter Methylation and mRNA Expression of Response Gene to Complement 32 in Breast Carcinoma
Table 1
Clinical and pathological characteristics of breast carcinoma patients.
| | Characteristics | Cases (%) |
| | Tumor size (cm) | | | ≤2 | 18 (28.6) | | 2–5 | 44 (69.8) | | >5 | 1 (1.6) | | Number of positive nodes | | | 0 | 11 (25.0) | | 1–3 | 28 (65.9) | | 4–9 | 4 (9.1) | | ≥10 | 0 (0) | | Histological grade | | | I | 6 (9.5) | | II | 16 (25.4) | | III | 11 (17.5) | | IV | 18 (28.6) | | Unknown | 12 (19.0) | | Tumor stage | | | I | 10 (15.9) | | II | 31 (49.2) | | III | 14 (22.2) | | IV | 8 (12.7) | | Histology | | | Ductal carcinoma | 56 (88.9) | | Other | 7 (11.1) | | Estrogen receptor | | | Positive | 34 (54.0) | | Negative | 27 (42.9) | | Unknown | 2 (3.1) | | Progesterone receptor | | | Positive | 21 (33.3) | | Negative | 42 (66.4) | | HER2 | | | Positive | 26 (41.3) | | Negative | 37 (58.7) |
|
|
